glycosylated recombinant human interleukin-7 (CYT107) / Revimmune  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
2009-014406-34: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression

Ongoing
2
12
Europe
GLYCOSYLATED RECOMBINANT HUMAN INTERLEUKIN-7, MARAVIROC, RALTEGRAVIR, CYT107, SELZENTRY, CELSENTRI, ISENTRESS, SELZENTRY, CELSENTRI, ISENTRESS
ORVACS, KEYRUS BIOPHARMA, , Bettencourt-Schueller Foundation
HIV-1 Infection
 
 
2018-003977-93: International, multicenter, randomized, double-blinded, placebo-controlled study of Recombinant Interleukin-7 (CYT107) to restore absolute lymphocyte counts (ALC) in patients with Sepsis

Ongoing
2
40
Europe
CYT 107, Solution for injection
RevImmune, RevImmune
Sepsis, Sepsis, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-001786-36: Study of investigational medicinal product of CYT107 in patients with COVID-19 infection who have low number of lymphocytes in their blood (ILIAD 7 trial)

Ongoing
2
200
Europe
CYT107, Solution for injection
RevImmune SAS France, RevImmune SAS France
Lymphopenia and T cell exhaustion in COVID-19 patients, COVID-19 patients whose their number of lymphocytes in their blood is low, Diseases [C] - Virus Diseases [C02]
 
 
2020-001573-78: Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection

Ongoing
2
200
Europe
CYT 107, Solution for injection
RevImmune, RevImmune
SARSCo-V-2, SARSCo-V-2, Diseases [C] - Virus Diseases [C02]
 
 
ILIAD-7-US-O, NCT04426201: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( )

Terminated
2
10
US
CYT107, Interleukin-7, Placebo, Saline
Revimmune, Memorial Sloan Kettering Cancer Center, Amarex Clinical Research, M.D. Anderson Cancer Center, Cancer Research Institute, New York City
COVID-19, Lymphocytopenia
06/22
06/22
IMPULSE-7, NCT04154826: Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

Terminated
2
8
US
Recombinant human interleukin-7, CYT107
Revimmune, Washington University School of Medicine
Mycobacterium Infections, Nontuberculous
12/23
03/24
NCT03513952: Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Active, not recruiting
2
47
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Glycosylated Recombinant Human Interleukin-7, CYT-107, CYT107, Glycosylated rhIL-7, INTERLEUKIN-7 HUMAN RECOMBINANT, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
09/23
10/24
NCT03941769: 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

Completed
1/2
1
US
Recombinant Interleukin-7, CYT 99 007, CYT-107, IL-7, Lymphopoietin-1, Recombinant Human Interleukin-7
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cord Blood Transplant Recipient, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
03/23
03/23

Download Options